nVent Electric heads into its third-quarter report with an unusual disconnect. Management has raised its full-year outlook twice in a row by wide margins, data center sales are on pace to more than double, and margins have started expanding again. Yet the stock has fallen about 11% since the last report while the S&P 500 gained nearly 4%. The market is asking a simple question: is the order book still growing fast enough to justify the guidance, or did the June quarter mark the peak of the growth curve?
Newell Brands spent four years promising a turnaround, and last quarter it finally showed one. Sales grew for the first time in more than four years, the U.S. business expanded for the first time since the pandemic, and management raised every major piece of its full-year outlook. Yet the stock has fallen nearly 16% since that report while the S&P 500 gained about 4%. When the company reports third-quarter results before the market opens on October 30, the question is whether the growth turn holds, or whether the market's skepticism was justified.
OmniAb heads into its third-quarter report with an unusual setup: the stock has more than doubled since the last report, yet the quarter itself is expected to look far weaker than the one before it. That is not a sign of trouble so much as a feature of the business model. OmniAb licenses its antibody discovery platforms to drug developers and collects milestone payments as partner programs advance. Management has said 2026 milestone revenue is heavily front-loaded, so after a $13.4 million second quarter, the Street is bracing for a return to lumpy, low-single-digit millions.
Oil States International heads into its third-quarter report with an unusual split personality. Its backlog is the largest in more than a decade, its Downhole business has finally turned, and its revenue mix has shifted decisively toward offshore and international work. Yet three months ago management cut its full-year outlook because Middle East disruptions kept pushing customer orders to the right. The report due before the open on October 30 is the first real test of whether that reset was conservative enough, or whether more 2026 revenue is drifting into 2027.
OneMain Holdings spent its last earnings call telling investors that the worst of its credit cycle was behind it. Delinquencies had finally turned lower across early and late stages, originations were accelerating, and management voiced high confidence that losses would fall materially in the second half of 2026. The market has not bought the story yet. Shares have slipped about 7% since that report while the S&P 500 gained 4.5%, so the third-quarter release on October 30 arrives as a straightforward test: either the promised loss improvement shows up in the numbers, or the skeptics get fresh ammunition.
Piper Sandler heads into its third-quarter report having already told investors the good times would cool. After a record first half built on surging advisory fees and a sharp rebound in corporate financing, management warned that the back half would not match the roughly 30% growth pace of the front half, largely because the second half of last year set a very high bar. The market appears to have taken that warning to heart and then some. The open question on October 30 is whether the slowdown looks like the orderly, comp-driven deceleration management described, or something softer.
RBC Bearings heads into its fiscal second-quarter report with a peculiar mismatch. The operating story coming out of last quarter was arguably the strongest in a year, with revenue growth reaccelerating, margins hitting a peak and a fast-growing space business emerging as a new engine. Yet the stock has fallen 13.6% since that report while the S&P 500 gained 3.8%. When the company reports before the open on October 30, the question is whether a quarter of planned margin normalization can still convince investors that the uptrend is intact.
Regeneron heads into its third-quarter report with an unusual mix of tailwind and headwind arriving at the same time. This is the first quarter in which the company collects its full share of Sanofi collaboration profits, after fully repaying the development balance last quarter. It is also the first full quarter in which multiple biosimilar versions of the original Eylea 2mg compete in earnest. How those two forces net out will decide whether the recent reacceleration story holds.
Standard Motor Products enters its third-quarter report with a record second quarter behind it and a stock that has drifted lower anyway. The company posted record adjusted EBITDA, cut debt sharply and talked confidently about its prospects, yet it chose to reaffirm rather than raise its full-year outlook. That restraint now looks like the central clue. The back half of the year brings much harder comparisons, and this report will show whether management was being conservative or simply realistic.
Sanofi heads into its third-quarter report with an odd split personality. On the commercial side, the business has rarely looked better: sales growth accelerated for four straight quarters and management raised its full-year outlook last time out. Yet the stock has slipped since that upbeat call, sentiment has soured sharply, and Wall Street is bracing for earnings to fall from a year ago. The question for October 30 is whether a planned soft patch stays planned, or whether it starts to look like the momentum story is fraying.
Sensient Technologies has raised its outlook at three straight conference calls, and the most recent lift was a big one. Yet the quarterly estimate going into its third-quarter report looks surprisingly modest next to that enthusiasm. That gap between a company guiding to mid-to-high teens earnings growth for the year and a Street model calling for single-digit growth this quarter is the central tension heading into the October 30 release, due before the opening bell.
Verra Mobility heads into its third-quarter report with a stock that has lost more than a third of its value since the last release and now trades below $3. The question is no longer whether the rental car repricing will hurt, since management has already said it will. The question is whether the damage stays contained to what the company described in August, or whether the Avis and Hertz renewals turn out to be a deeper wound than the revised outlook implies.
Three months ago, Virtus Investment Partners delivered its most encouraging quarter in more than a year. Net outflows nearly halved, institutional sales doubled and management said that, for the first time in a long while, almost every one of its quality-equity strategies was beating its benchmark. The market has not bought it. The stock has fallen about 27% since that report while the S&P 500 gained 5%, and it now trades near $119, a hair above its post-earnings low of $117.44 and well beneath both its 200-day moving average near $147 and the prior quarter's floor of $127. The third-quarter report, due before the open on October 30, has to answer whether the turn was real or a one-quarter mirage.
WisdomTree heads into its third-quarter report with an odd-looking setup. Revenue is expected to keep climbing, the Atlantic House acquisition will contribute for a full three months for the first time, and the share count is shrinking from buybacks. Yet consensus calls for earnings of $0.30 a share, a penny below the $0.31 the company posted last quarter. Either analysts are building in real cost or revenue headwinds, or they are leaving the company room to clear a modest bar. Thursday morning's release should show which.
Exxon Mobil heads into its third-quarter report with an unusual math problem. Wall Street expects revenue to fall sequentially, yet earnings per share to climb. That only works if the margin story management told last quarter, built on tight refining markets, rebounding chemicals and a Guyana cash machine moving into a richer phase, is holding up even as roughly a tenth of upstream production remains sidelined by the Middle East conflict.
AutoNation heads into its third-quarter report with a striking disconnect. Three months ago management sounded more confident than it had in some time, pointing to a sixth straight quarter of year-over-year EPS growth, record after-sales profit and a finance arm that is finally earning real money. The market has spent the period since then betting against that story. Shares have fallen 22.7% since the last report while the S&P 500 gained 3.8%, leaving the stock at $153.01, barely above its post-earnings low of $151.82 and far below its 200-day moving average of $195.39. This report has to show whether the confident tone was justified or whether the stock's slide was picking up on something real.
Capital Clean Energy Carriers enters its September-quarter report with an awkward split between business and stock. Management sounded more confident last quarter than it has in some time. It cited record fleet deliveries, a growing contracted backlog and a spot LNG market lifted by Middle East disruption. Yet the shares have fallen 12% since that report while the S&P 500 gained about 3%. The upcoming release needs to show that the newly delivered ships are turning into earnings at the pace the Street assumes, and that the strain on the balance sheet is a peak rather than a trend.
IRadimed spent its last earnings call making a case that flat revenue was hiding a business on the verge of acceleration. Its new 3870 MRI-compatible infusion pump was off to a faster start than planned, bookings were running at more than twice shipments, and customers were buying pricier configurations than anyone expected. The third-quarter report is where that story has to show up in the numbers, because management has effectively promised a steep production ramp, a sequential revenue jump and the start of a margin recovery all at once.
JinkoSolar heads into its third-quarter report with the stock down 45% since its last update and a narrative in flux. Three months ago management slashed its full-year module shipment target, watched gross margin halve, replaced its founder as chief executive and began recasting the company as an investment platform with stakes in AI, robotics and quantum computing. The question for Thursday's pre-market release is simple: was the second quarter the trough, or the start of something worse?
Brookfield Corporation enters its third-quarter report with an awkward contradiction. Last quarter's call was the most confident in a year, with fundraising at a record, fee-bearing capital climbing and several huge AI and nuclear projects moving from wish list to signed paper. Yet the stock has fallen 18.7% since that report, trailing the S&P 500 by nearly 18 percentage points. When the release arrives after the close on November 11, the question is less whether Brookfield can grow and more whether the market believes the quality of that growth.